Abstract
Antibiotic research has been hindered by a perfect storm consisting of scientific challenges, regulatory uncertainties, difficult markets, and industrial consolidation. At the same time, antibiotic resistance is making the medical need for a robust antibiotic pipeline ever more urgent. The Food and Drug Administration in the United States, following their European colleagues, has made important progress in correcting its position as part of this perfect storm and in providing less expensive and streamlined pathways for antibiotic development. But the economics of antibiotic development and marketing remains a potential stumbling block to reinvigorating antibiotic research within the pharmaceutical industry. The current situation is reviewed in this viewpoint article.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
